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Abstract
Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in
40–60% of cancer patients. It has been suggested that genetic variants in the
genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-
methyltransferase (COMT) can predict the development of cisplatin-induced
ototoxicity and may explain interindividual variability in sensitivity to cisplatin-
induced hearing loss. Two recently published studies however, sought to validate
these findings and showed inconsistent results. The aim of this study was to
evaluate the role of polymorphisms in the TPMT and COMT genes in cisplatin-
induced ototoxicity. Therefore we investigated two independent cohorts of 110
Dutch and 38 Spanish patients with osteosarcoma and performed a meta-analysis
including all previously published studies resulting in a total population of 664
patients with cancer. With this largest meta-analysis performed to date, we show
that the influence of TPMT and COMT on the development of cisplatin-induced
hearing loss may be less important than previously suggested.
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Introduction
Cisplatin is an effective chemotherapeutic drug for several types of cancer such as
ovarian cancer, lung cancer, osteosarcoma and neuroblastoma. Ototoxicity,
characterized as a permanent, bilateral sensorineural hearing loss, is one of the
most common side effects of cisplatin and occurs in 40–60% of patients [1].
Ototoxicity is one of the main reasons for dose reduction or termination of
treatment with cisplatin treatment. Clinical risk factors for the development of
cisplatin-induced ototoxicity have been described such as age younger than 5
years at diagnosis [2, 3], concurrent medication like carboplatin [4] as well as
higher cumulative doses [2, 4], cranial radiation [5] and pre-existing renal
dysfunction. Nevertheless, these clinical factors are not sufficient to reliably
predict ototoxicity before the start of treatment. A candidate gene study in 166
pediatric patients suggested that genetic variants in the genes encoding thiopurine
S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can
predict the development of cisplatin-induced ototoxicity and may explain the
interindividual variability [6]. Two recently published studies, developed to
validate these findings, showed inconsistent results. Pussegoda and colleagues
confirmed the findings of Ross et al. for variants in the TPMT gene in a cohort of
155 patients however, with smaller effect sizes compared to the original findings
[7]. In contrast, no association of TPMT or COMT and ototoxicity was found in a
cohort of 213 patients with medulloblastoma [8]. Based on these three studies no
recommendation for clinical implementation regarding genetic variants in TPMT
and COMT and ototoxicity can be made. The aim of the current study is to
provide a clearer picture of the genetic impact of TPMT and COMT variants on
developing cisplatin-induced ototoxicity. Therefore we investigated two inde-
pendent cohorts of 110 Dutch and 38 Spanish patients with osteosarcoma and
performed a meta-analysis including previously published studies [6–8] resulting
in a total population of 664 patients with cancer.
Materials and Methods
Dutch cohort
A cohort of 110 Dutch patients with high-grade osteosarcoma treated with
cisplatin was recruited from the Radboud University Medical Centre, the
University Medical Centre of Groningen and Leiden University Medical Center.
All patients were treated with cisplatin with a median cumulative dose of 500 mg/
m2 (range: 100 to 600 mg/m2). Of patients included audiometric analysis were
available at diagnose, during therapy and after completion of therapy. Data
concerning administration of other potentially ototoxic medications such as
furosemide, vancomycin, gentamicin, tobramycin, amphotericin B, carboplatin
and vincristine, were recorded. In patients alive, DNA was extracted from blood
using the QIAamp DNA Blood Midi kit (Qiagen Venlo, The Netherlands) or
saliva (2 ml) using the Oragene DNA purification protocol (DNA Genotek,
Kanata, Ontario, Canada). Of patients that passed away, (N539, 26.5%, median
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follow up time 2.3 years with range 1.1–5.5 years), DNA of paraffin-embedded
samples was extracted as recently described [9]. The study was approved by the
ethics committee from the Radboud University Medical Centre as the central
committee for this study for the Netherlands and written informed consent was
obtained from parents and/or patients
Spanish cohort
To enlarge sample size for meta-analyses, we additionally included an
independent Spanish cohort of osteosarcoma patients who were treated with
cisplatin-containing regimens. To prevent population bias, this cohort was
analyzed separately. In total, 38 patients with osteosarcoma were included on the
basis of availability of germline DNA and audiologic assessment at least one
month after initial treatment. Data regarding ototoxic medication were available.
The study was approved by the local ethics committee from the University of
Navarra and University Clinic in Pamplona. Written informed consent was
obtained from parents and/or patients.
Ototoxicity
In both cohorts audiologic evaluations were prospectively performed at diagnosis,
during therapy and after completion of therapy. First audiological follow-up was
performed 1–3 months after completion of therapy and thereafter annually. All
audiometric assessments were age appropriate performed by conventional or play
audiometry under standardized conditions as part of routine clinical monitoring
for cisplatin-related hearing loss. Hearing loss was retrospectively classified
according to two grading systems: the National Cancer Institute CTCAE version
3.0 (http://ctep.cancer.gov/forms/CTCAEv3.pdf) and the new SIOP Boston
ototoxicity scale which classifies hearing loss on the basis of absolute hearing levels
in 4 grades [10]. The most recent audiologic assessment during follow-up period
after the last cisplatin course was used for analysis.
Genotyping
Previously associated variants in TPMT (rs12201199: C__31923406_10,
rs1800460: C__30634116_20, rs1142345: C_____19567_20) and COMT
(rs4646316: C__29193982_10, rs9332377: C__29614343_10) were genotyped
using Taqman allelic discrimination assays according to the protocol of the
manufacturer (Invitrogen, Bleiswijk, The Netherlands). After amplification, the
fluorescent signal for allelic discrimination was determined using the 7500 Fast
Real-time System (Invitrogen). Automated allele calling was performed by allelic
discrimination plots using SDS 1.4 software (Invitrogen).
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SNP analysis
In both cohorts, statistical differences regarding demographic data between
patients who developed hearing loss (cases;.20 dB hearing loss above 4 kHz) and
patients without hearing loss (controls; #20 dB hearing loss at all frequencies)
were assessed by the Fischer exact test. Reported p-values are two-sided and are
considered statistically significant if ,0.05. Associations between ototoxicity and
potential confounders, such as age, gender, cumulative dosage of cisplatin and
concomitant drugs were evaluated using a 262 table (in case of dichotomized
variables) or linear regression (in case of linear variables) in SPSS version 20 (SPSS
Inc., Chicago, Il). To assess the effect of the genetic variants on ototoxicity data
were dichotomized in grade 0 vs. grade 2–4. Multivariate logistic regression
analyses included vincristine exposure as confounder in PLINK [11] using the
command –logistic.
Meta-analyses
We searched PubMed for papers using the keywords: ‘ototoxicity’, ‘TPMT’ and
‘COMT’. Since the publication of Ross and colleagues [6] in 2009 only two other
studies [7, 8] evaluated the association of the COMT and TPMT variants in cancer
patients. Meta-analysis was performed on these three previously published studies
and the two cohorts presented in this study were included. Of each of the five
studies the CTCAE hearing loss criteria were used, excluding patients with grade 1
ototoxicity to better differentiate between cisplatin-induced ototoxicity and
normal hearing. The studies were weighed using the inverse variance method,
where larger studies with smaller standard errors have more weight than smaller
studies with larger errors (Review manager 5.0, The Cochrane Collaboration,
Oxford, UK). Heterogeneity among studies was examined with I2 statistics that
can be interpreted as the proportion of total variation contributed by between-
study variation. Allelic odds ratio (OR) were recalculated dependent on the
number of cases and controls in each cohort and 95% confidence interval (CI)
were estimated using a fixed effects model or random effects models in case large
heterogeneity I2.50% was observed.
Results
Dutch cohort
A total of 110 patients with Dutch ancestry and newly diagnosed osteosarcoma
were included of whom 42 (38.2%) developed.20 dB hearing loss above 4 kHz.
Characteristics of patients divided in patients with hearing loss (cases;.20 dB
hearing loss above 4 kHz) and patients without hearing loss (controls; #20 dB
hearing loss at all frequencies) are depicted in Table 1. Baseline characteristics did
not show statistically significant differences between the two groups. None of the
patients included was treated with cranial irradiation or with concomitant
ototoxic antibiotics. Only five patients were additionally treated with vincristine.
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Other ototoxic chemotherapeutics were not administered. In 23 (20.9%) of all
patients cumulative dose of cisplatin was reduced due to ototoxicity (N59,
.20 dB hearing loss above 4 kHz) or other cisplatin-induced toxicity (N514).
Baseline audiograms were available in 87 patients (79%) showing normal baseline
hearing thresholds (#20 dB) in all patients. Median follow up period was 5.2
years (range 23–7763 days). Different ototoxicity grading systems were used to
exclude biased dichotomisation. For the CTCAE criteria, 80 patients with baseline
audiogram were included. Patients with grade 1 ototoxicity (N57) were excluded
in order to use same inclusion/exclusion criteria as previous studies in literature
[6–8]. Classification according to the CTCAE criteria showed in all but seven
patients identical toxicity grades when compared to the SIOP grading system.
Four patients with grade 1 and three patients with grade 2 ototoxicity according to
the SIOP Boston ototoxicity scale were upgraded to grade 2 and 3 according the
CTCAE criteria. Hearing loss grade 2–4 was seen in 23 patients graded according
the CTCAE criteria (0 vs. 25 dB at 4–8 kHz) and 22 according to the SIOP
criteria (0 vs. 20 dB at 4–8 kHz). Univariate analysis showed no association with
non-genetic factors previously reported to be associated with ototoxicity: age
(p50.73) and cumulative dose of cisplatin (p50.99).
Spanish cohort
To enlarge sample size for the meta-analyses we included another cohort of 38
Spanish patients of European ancestry with osteosarcoma (Table 1). No
statistically significant differences concerning age, gender or cumulative dose of
cisplatin was seen between patients with hearing loss (cases; .20 dB hearing loss
above 4 kHz) and patients with normal hearing (controls; #20 dB hearing loss at
all frequencies). None of the included patients was additionally treated with
Table 1. Demographic data of the Dutch and Spanish cohort.
Dutch cohort Spanish cohort
Cases Controls Cases Controls
5 Ototoxicity 5 No ototoxicity 5 Ototoxicity 5 No ototoxicity
N542 N568 p-value N516 N522
p-
value
Age at diagnosis (y) 15 15 0.82 11.5 14 0.23
median, range (5–40) (7–39.3) (4–29) (7–28)
Gender (male) 22 33 0.6 15 6 0.1
N, % (40%) (60%) (71.4%) (28.6%)
Cumulative dose cisplatin (mg/m2) 500 480 1 504 515 0.32
median, range (100–600) (200–600) (120–870) (140–720)
Concomitant drugs
Vincristine (N, %) 3 (2.7%) 2 (1.8%) 0.3 2 (5.2%) 4 (10.5%) 0.13
Aminoglyocide antibiotics (N, %) 0 0 15 (68.2%) 10 (62.5%) 0.74
Otoprotectants (N, %) 0 0 0 0
doi:10.1371/journal.pone.0115869.t001
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cranial irradiation. Regarding concomitant medication, all but six patients were
additionally treated with vincristine and 23 patients received ototoxic antibiotics,
such as vancomycin, gentamicin or tobramycin. In univariate analysis the use of
these antibiotics was not a confounding factor to develop ototoxicity in this
cohort (p50.74). As to the small sample size and to prevent population bias due
to ethnicity, genotyping results of this cohort were analyzed as an independent
cohort in the meta-analyses.
Genotyping
We genotyped three variants in the TPMT gene (rs12201199, rs1800460, and
rs1142345) and two in the COMT gene (rs4646316, rs9332377). No deviation
from Hardy–Weinberg equilibrium was observed. Irrespective of the grading
system used (CTCAE or SIOP), association analysis using an additive genetic
model correcting for usage of vincristine, showed no association between genetic
variants in TPMT or COMT with an increased risk of ototoxicity in the Dutch
cohort (S1 Table, S2Table and S3 Table).
Meta-analyses
So far, three studies with four independent cohorts studying the influence of
TPMT and COMT on the development of ototoxicity have been published [6–8].
With this study we add two additional independent cohorts. In all studies the
CTCAE criteria were reported. To better differentiate between cases and controls
all studies excluded patients with grade 1 ototoxicity. In total, 664 patients were
included in the meta-analyses. Table 2 shows the demographic data of the initial
studies, as well as the number of patients per study that were included in the
meta-analysis. In Figs. 1 and 2 odds ratios for each individual study are presented.
The genetic variant rs4646316 in the COMT gene was the only significant
association with ototoxicity (OR A versus T allele: 1.52, 95% CI: 1.16–1.99,
P50.003; Fig. 2). The heterogeneity test showed a non-statistically significant
heterogeneity with an I2 of 31%. Notably, there are substantial differences in the
range of the ‘‘total events’’ captured between the meta-analyses which is related to
incomplete genotyping in all studies, except for the study of Pussegoda and
colleagues [7].
Discussion
Although, the results of Ross and colleagues investigating the influence of variants
in TPMT and COMT were very promising [6], the outcome of more recent studies
argues against the premise that these variants might help to identify patients at
risk for ototoxicity. In the present study, therefore, we aimed to gain a clearer
picture on the role of these variants by adding additional data on the subjects, and
by performing a meta-analysis including two new cohorts.
Role of Pharmacogenetics in Cancer Patients with Ototoxicity
PLOS ONE | DOI:10.1371/journal.pone.0115869 December 31, 2014 6 / 13
T
a
b
le
2
.
D
e
m
o
g
ra
p
h
ic
d
a
ta
o
f
p
a
tie
n
ts
w
ith
o
to
to
xi
ci
ty
in
cl
u
d
e
d
fo
r
m
e
ta
-a
n
a
ly
si
s.
C
a
s
e
s
/T
o
ta
l
E
th
n
ic
it
y
A
g
e
(y
)
T
y
p
e
s
o
f
c
a
n
c
e
r
G
e
n
d
e
r
o
f
c
a
s
e
s
C
u
m
u
la
ti
v
e
d
o
s
e
C
ra
n
ia
l
ir
ra
d
ia
ti
o
n
O
to
p
ro
te
c
ta
n
t
V
in
c
ri
s
ti
n
e
A
m
in
o
g
ly
c
o
c
id
e
N
M
e
d
ia
n
M
a
le
%
M
e
d
ia
n
(m
g
/m
2
)
%
u
s
e
d
a
n
ti
b
io
ti
c
s
R
o
ss
e
t
a
l.6
1
0
6
/1
6
2
M
ix
e
d
p
o
p
u
la
tio
n
6
D
iff
e
re
n
t
ca
n
ce
rs
6
7
.0
%
4
0
0
m
g
/m
2
1
8
.5
0
%
N
o
in
fo
rm
a
tio
n
Y
e
s
Y
e
s
P
u
ss
e
g
o
d
a
e
t
a
l.7
8
7
/1
5
5
M
ix
e
d
p
o
p
u
la
tio
n
6
D
iff
e
re
n
t
ca
n
ce
rs
4
9
.4
%
4
0
0
m
g
/m
2
1
8
%
N
o
in
fo
rm
a
tio
n
Y
e
s
Y
e
s
Y
a
n
g
e
t
a
l.,
ra
d
ia
tio
n
co
h
o
rt
8
1
3
1
/1
9
5
M
ix
e
d
p
o
p
u
la
tio
n
7
M
e
d
u
llo
b
la
st
o
m
a
6
8
.8
%
*
3
0
0
m
g
/m
2
*
1
0
0
%
*
Y
e
s
Y
e
s
N
o
in
fo
rm
a
tio
n
Y
a
n
g
e
t
a
l.,
n
o
ra
d
ia
tio
n
8
3
5
/3
8
M
ix
e
d
p
o
p
u
la
tio
n
8
M
e
d
u
llo
b
la
st
o
m
a
6
5
.0
%
5
0
0
m
g
/m
2
0
Y
e
s
Y
e
s
N
o
in
fo
rm
a
tio
n
H
a
g
le
itn
e
r,
th
is
st
u
d
y
2
2
/8
0
D
u
tc
h
a
n
ce
st
ry
1
5
O
st
e
o
sa
rc
o
m
a
4
0
.0
%
5
0
0
m
g
/m
2
0
N
o
Y
e
s
N
o
P
a
tin
o
-G
a
rc
ia
,
th
is
st
u
d
y
1
8
/3
4
E
u
ro
p
e
a
n
a
n
ce
s-
tr
y
1
2
O
st
e
o
sa
rc
o
m
a
5
5
.3
%
5
0
0
m
g
/m
2
0
N
o
Y
e
s
Y
e
s
*d
a
ta
o
f
to
ta
l
g
ro
u
p
a
s
p
u
b
lis
h
e
d
b
y
Y
a
n
g
e
t
a
l.
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
15
86
9.
t0
02
Role of Pharmacogenetics in Cancer Patients with Ototoxicity
PLOS ONE | DOI:10.1371/journal.pone.0115869 December 31, 2014 7 / 13
Our Dutch dataset of 110 uniformly treated patients with osteosarcoma, is a
homogenous group without potentially confounding factors such as cranial
radiation and concomitant medication. For classification of cisplatin-induced
hearing loss, we preferred to use the SIOP Boston scale as it combines the two
main types of measuring ototoxicity, namely changes of hearing from baseline as
Fig. 1. Forest plots genetic variants in TPMT gene.
doi:10.1371/journal.pone.0115869.g001
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well as absolute hearing levels [10]. As previously published studies used the
CTCAE criteria for the classification of ototoxicity, we reclassified our data
according to the CTCAE criteria, and excluded grade 1 ototoxicity to better
distinguish between cases and controls. In the Dutch cohort, and also the other
newly analyzed Spanish cohort, we did not observe any statistically significant
association between the genetic variants in TPMT, COMT and ototoxicity. We did
observe differences between the two cohorts such as lower ototoxicity rate in the
Dutch cohort which might be explained by the inclusion of adults until the age of
40 years. It is known that young children are more susceptible to ototoxicity from
cisplatin [3]. Furthermore, the Dutch cohort included patients who have already
died. It might be that controls that died have become cases if they have survived
longer. However, the median follow up time of these patients who have died was
2.3 years with a range between 1.1 and 5.5 years. Studies included in this meta-
analysis showed universally that the majority of ototoxicity occurred between 0.5
and 6 months from start of cisplatin chemotherapy [6–8].
After meta-analyses of the genetic variants in TPMT and COMT including in
total 664 patients only rs4646316 variant in the COMT gene remained statistically
Fig. 2. Forest plots genetic variants in COMT gene.
doi:10.1371/journal.pone.0115869.g002
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significant. However, the effect was much smaller than reported in previously
published studies. In the initial discovery cohort of Ross and colleagues the OR of
this variant to develop ototoxicity was 2.5 (95% CI: 1.5–4.3) [6]. Whereas the
combined effect of all studies included in the meta-analysis showed an OR of 1.52
(95% CI: 1.16–1.99). Three of the cohorts (excluding the initial study by Ross et
al.) showed the same direction of effect for rs4646316, however, this was not
statistically significant. The COMT gene encodes for the COMT enzyme which is
involved in the inactivation of catecholamine neurotransmitters. Although, it has
been shown that it is also highly expressed in sensory hair cells of the inner ear, its
role regarding auditory function remains unclear [12]. In addition, the influence
of the variant rs4646361 on the COMT enzyme has not been studied yet.
Generally, the association between TPMT variants and cisplatin ototoxicity was
unexpected [9], as it was not previously linked to cisplatin metabolism. Recent
published data support the hypothesis that TPMT might have an influence on
cisplatin metabolism by increasing levels of S-adenosylmethionine (SAM) [13].
Furthermore, a recent study demonstrated that functional TPMT variants were
associated with progression-free survival in cisplatin-based chemotherapy
outcomes in ovarian cancer [14]. However, in vivo studies in mice with different
TPMT genotypes showed no differences in hearing damage between TPMT wild-
type and knockout mice [8].
With the largest meta-analysis performed to date we show that the influence of
TPMT and COMT on the development of cisplatin-induced hearing loss may be
less pronounced than previously suggested. This lack of association observed
might be attributable to heterogeneity between the different studies as shown in
Table 2. First, different patient populations with different ethnicities were used in
the studies which could account for the differences in the genetic associations in
the meta-analysis. Second, in the study cohorts with clear positive association, a
heterogeneous group of patients with respectively 9 and 12 different types of
cancers was included [6, 7]. As a consequence, patients were treated with different
treatment regimens sometimes including cranial irradiation and different co-
medication. In these studies an analysis for specific patient subgroups was not
performed probably due to the limited number of patients included for each
subgroup. Also the cohorts with clear negative association included patients with
different cancer types, one study included patients with osteosarcoma (this study)
as in the study of Yang et al. patients with medulloblastoma have been included
which necessitates highly different treatment protocols regarding cumulative dose
of cisplatin, cranial radiation and concomitant medication. Third, the different
types of cancer were not equally distributed among patients with and without
ototoxicity, for example in the cohort of solid tumors investigated by Yang and
colleagues 35 of the 38 patients [8] were reported to have hearing loss which may
lead to selection bias. Fourth, the median cumulative doses of cisplatin ranged
from 300 to 500 mg/m2 in the different studies. However, neither in the study
cohort of medulloblastomas with a relatively low cumulative dose of cisplatin [8]
nor in osteosarcoma patients treated with higher doses of cisplatin (this study), an
association was found. In addition, young age has recently been pointed out as an
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important factor to develop cisplatin-induced hearing loss [3], which may be the
reason for the lower incidence of ototoxicity in the osteosarcoma cohort as the
median age at diagnosis is older compared to the other cohorts. At last, the use of
otoprotective agents, such as amifostine, may be a potentially confounding factor.
A Cochrane study on this topic was due to methodological limitations of
individual studies unable to show evidence of effect to use amifostine as an
otoprotective intervention [15]. However, there was also no evidence that it had
no effect as otoprotectant. In the study of Yang et al the use of amifostine was
linked to less ototoxicity [8].
It is clear that all studies included in this meta-analysis have confounding
variables which could potentially influence the development of ototoxicity. This is
important given the inverse method of weighing studies which has been used in
this meta-analysis. The studies of Pussegoda et al and Yang et al were consistently
attributed the highest weighting. Pussegoda et al included a diverse population of
different cancers with different treatment protocols, the youngest population in
this meta-analysis with different follow-up time between cases (5 years follow-up)
and controls (2 years follow-up). The radiation cohort of Yang et al patients
received highly ototoxic cranial irradiation, but 90% also received an
otoprotectant, and overall these patients received a significantly lower cumulative
dose of cisplatin. Thus, the weight attributed to a study may affect the results of
the meta-analysis, however this is something that cannot be circumvented in this
type of analysis.
Nevertheless, younger age and higher cumulative doses of cisplatin appear to be
the most consistent risk factors for ototoxicity. However, an upfront risk
stratification based on these two factors is unreliable as these factors seem to be
protocol specific and dose adjustments may jeopardize treatment efficacy of
cisplatin. The addition of otoprotective agents in combination with cisplatin
might be an alternative treatment strategy to prevent hearing loss. Although, the
mechanism of cisplatin-induced hearing loss is not fully understood, several
preclinical studies have shown that in the cochlear cells cisplatin induces the
production of toxic levels of reactive oxygen species (ROS) which can initiate
cochlear cell death leading to hearing loss [16, 17]. Numerous studies have
investigated a variety of antioxidant agents to protect cochlea cells from cisplatin
damage. Among them, sodium thiosulfate, D or L-methionine, glutathione ester
and amifostine were successfully tested in animal models [18, 19]. The efficacy of
otoprotective agents in patients is however disappointing. For instance, sodium
thiosulfate showed an unwanted compromised antitumor effect of cisplatin [20]
and no otoprotection was observed in children with germ cell tumors treated with
amifostine in combination with cisplatin [21].
It remains challenging to find the right balance to maintain antitumor effect of
cisplatin and on the other hand to prevent unwanted adverse effects. Innovative
studies translating basic science into clinical practice are needed to unravel both,
the mechanism of cisplatin-induced hearing loss and identification of patients at
risk to develop ototoxicity. Pharmacogenetics may help to find new target genes,
unfortunately it seems that the genes TPMT and COMT play only a minor role in
Role of Pharmacogenetics in Cancer Patients with Ototoxicity
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cisplatin-induced ototoxicity and should therefore not guide clinical decision
making for cisplatin dosing.
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